Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

C-Bridge In-Licenses China Rights to Three Samsung Bioepis Biosimilars

publication date: Feb 11, 2019

China's C-Bridge Capital in-licensed China rights to three biosimilar candidates from Korea's Samsung Bioepis Co. C-Bridge will form a new company, AffaMed Therapeutics, which will be in charge of clinical development, regulatory registration and commercialization. The agreement includes third-wave biosimilar candidates to macular degeneration treatment Lucentis® (ranibizumab), rare disease treatment Soliris® (eculizumab), and breast cancer drug Herceptin® (trastuzumab). Terms of the agreement were not disclosed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai , China
May 8-9, 2019
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China